Ziihera Regimens Show 27-Month Median Survival at Three Years in First-Line HER2+ GEA
JAZZ sits 65% above its 52-week low of $128.8.
Summary
Mature HERIZON-GEA-01 data presented at ESMO 2026 show Ziihera plus tislelizumab and chemotherapy kept median overall survival at 27.0 months versus 19.6 months for trastuzumab plus chemotherapy, cutting the risk of death by 35% (HR 0.65) — better than the 0.72 hazard ratio at the first interim. Nearly 40% of patients on that triplet were alive at three years, versus 22.9% on trastuzumab plus chemotherapy. Ziihera plus chemotherapy alone also cleared statistical significance against trastuzumab plus chemotherapy (22.9 vs 19.6 months; HR 0.76; P=0.0088), a claim the first interim could not make. This is the confirmatory survival package behind the August 25 FDA first-line approval and the recent NCCN preferred-therapy listing, and it strengthens the case for Ziihera as the HER2-directed backbone in first-line GEA. The triplet-versus-doublet comparison (27.0 vs 22.9 months) trended favorable but missed significance at P=0.0502, so the incremental benefit of adding tislelizumab remains the open question. Ziihera booked $15.4M in Q2, so first-line GEA uptake is the number to track in the next quarterly report.
At the time of this announcement, JAZZ was trading at $212.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $128.80 to $266.38. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.